Detailed narrative
Top-line strength and a healthy capital-equipment backdrop
Q1 revenue was $5.1B, up 2.9% organic and at the high end of expectations, with reported product and service growth of 7.3% and 7.5%. Demand was broad: EMEA and Rest of World grew double digits reported, the US mid-single digits, and China declined YoY but improved sequentially and was in line.
Orders grew 1.1% against a tough 10.3% prior-year comp, book-to-bill was 1.07x, and backlog hit a record $21.8B, up $1.2B YoY. Management characterized the global capital-equipment market as healthy with resilient procedure growth, and pointed to equipment book-to-bill running above the blended figure.
Profit and cash-flow guidance cut on input-cost inflation
Management reduced 2026 profit and FCF guidance while holding the top line. Gross inflation is ~$250M ($0.43/share): ~$100M from a jump in memory-chip prices, ~$100M from oil and freight, and ~$50M of other commodities such as tungsten. Costs are assumed to stay at today's elevated levels with no additional cushion.
Price and cost actions (~$0.23 of offsets) offset more than half, but land mainly in Q3/Q4 because much of 2H's revenue is already in backlog and price applies to new orders. Adjusted EPS guidance was cut $0.15 to $4.80-$5.00, EBIT margin to 15.4%-15.7%, and FCF to ~$1.6B; inflation impact is minimal in Q1 (FIFO), building through 2H.
Segment realignment to three segments (AIS)
GE HealthCare is combining Imaging and Advanced Visualization Solutions into a new Advanced Imaging Solutions (AIS) segment led by Phil Rocklin, moving from four segments to three (AIS, PDx, PCS). The stated rationale is a higher growth profile via faster, more differentiated commercial storytelling and streamlined R&D allocation across clinical pathways (e.g., structural heart/cardiology spanning CT, ultrasound and cath-lab guidance), with cost benefits secondary.
A new global markets region under Katrina Trump was also announced. Recasted AIS financials will accompany Q2 reporting. PCS becoming a standalone segment enables a strategic portfolio assessment.
Innovation cycle: Photon Counting CT and next-gen MR
The company received US and Japan clearances for Photonova Spectra, its Photon Counting CT platform, positioning it at the ultra-high end with spectral/soft-tissue differentiation and no image-quality trade-offs; the sales funnel exceeds $100M, with 4-6 months of customer assessment then 5-8 months to sales conversion, typically starting with installed-base conversion.
Separately, CT is already growing well on Revolution Vibe (cardiac). MR secured multiple FDA clearances including a new 3T reduced-Helium platform and an AI-powered workflow. Revenue from these key imaging NPIs is expected to begin in H1 2027.
Radiopharmaceuticals and the Flyrcado ramp
PDx grew 9.7% organic on contrast media, radiopharmaceuticals and molecular-imaging equipment. Flyrcado doses rose ~80% since late January to 390 in the week ended April 17, lifting the annualized run-rate from ~$25M to ~$46M in April. About 31 CMOs are now active and performing, with a >95% delivery-rate target; the customer base grew roughly in line with volume.
Gating factors are supply/CMO capacity and customers ramping utilization. Management reaffirmed a $500M+ 2028 target and framed Flyrcado as a potential $1B molecule. Amyloid-beta imaging is also accelerating on expanding Alzheimer's disease-modifying therapy use.
Gadolinium-free MRI contrast agent
GE HealthCare dosed the first patient in a combined Phase II/III study of a novel manganese-based, gadolinium-free MRI contrast agent under FDA Fast Track, following a successful Phase I (historically where such agents failed on tox/adverse events) and supportive Mayo Clinic work.
The proprietary formulation aims to match gadolinium image quality while clearing the body and removing retention and rare-earth-sourcing concerns, addressing a $1.2B contrast MR market. If successful, Fast Track plus the combined study could pull a launch into ~2029 versus ~2030.
Patient Care Solutions weakness and mitigation
PCS organic revenue fell 8.1% YoY with EBIT margin down 500 bps, driven by large monitoring installations concentrated in 2H (which carry most of the margin) and by tariffs; the decline was broadly in line with a cushioned expectation but larger in magnitude than desired.
Total segment orders grew. Mitigation centers on backlog conversion (well-established monitoring customers), pricing, cost-structure optimization, and a strategic portfolio assessment now that PCS is a standalone segment. A first new premium anesthesia product in years is expected to clear in Q3 as an orders/sales driver.
Capital allocation, M&A and competitive context
FCF was $112M, up $13M YoY on working-capital gains. The company repaid $500M of debt, repurchased ~$100M of shares and paid its dividend. Priorities remain organic investment (protecting R&D and commercial spend), disciplined ROIC-accretive M&A (Intelerad closed in Q1; extends cloud/outpatient enterprise imaging with >30% EBITDA margins and double-digit growth), and opportunistic buybacks when shares trade below intrinsic value.
On PDx generics, management sees no impact yet, views it as more a 2027 dynamic, and notes the market is already a branded-generic/AB-rated field managed via full SKU breadth, contracting and supply resilience.